Takeda Halts Prostate Cancer Vaccine Development
This article was originally published in PharmAsia News
Executive Summary
Takeda announced Oct. 17 that the company has decided to halt developing GVAX, a prostate cancer vaccine jointly developed with the U.S. biopharmaceutical company Cell Genesys. The decision is based on clinic trials conducted on 626 patients in Europe and the U.S., and the studies have not shown effective results in prolonging lives. Analysis shows the trial had less than a 30 percent chance of meeting its predefined primary endpoint of improvement in survival. Takada has been financing the development. (Click here for more - Japanese language
You may also be interested in...
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.